About the Study: Among patients undergoing urgent coronary intervention for acute myocardial infarction, starting evolocumab before or during the procedure produced faster and more sustained LDL cholesterol lowering than a conventional stepwise treatment approach. However, this strategy did not reduce death or unplanned cardiovascular hospitalization during the first year. The findings do not support the assumption that lowering LDL cholesterol as rapidly as possible with a PCSK9 inhibitor immediately after myocardial infarction necessarily improves short-term clinical outcomes.
Meeting Information: ESC 2026
This paper will be presented during European Society of Cardiology Congress in Munich, Germany.
Local Embargo Time: 8:30 A.M. CEST.
ESC Presentation: Gilles Montalescot will simultaneously present the findings during the Hot Line 2 session in the Main Auditorium.
Related Content: This paper has an accompanying editorial .
